Mallinckrodt plc, a global specialty pharmaceutical company announced that it has appointed Susan Silbermann to its Board of Directors, effective October 5, 2022. With the addition of Ms. Silbermann, the Mallinckrodt Board will expand to nine directors, eight of whom are independent.
"Susan is a highly respected and deeply experienced global executive in the healthcare industry, and we are pleased to welcome her to Mallinckrodt's Board," said Paul Bisaro, Chairman of the Mallinckrodt Board of Directors. "Susan brings an important perspective, with decades of leadership experience across established and unique healthcare brands. We look forward to benefiting from her deep expertise and insights as we continue to strengthen the organization, sharpen our execution and deliver innovative therapies for patients."
"I am excited to join the Mallinckrodt Board at this transformative moment for the Company," said Ms. Silbermann. "With a strong platform in place, I see compelling opportunities ahead to grow the business, develop the pipeline and, most importantly, serve the many patients who can benefit from Mallinckrodt's products. I look forward to helping the Company deliver on its patient-first business priorities as we generate long-term value for Mallinckrodt shareholders."
During her 34-year career at Pfizer, Ms. Silbermann held numerous positions of increasing responsibility spanning public health, marketing, commercial development and general management in U.S. and international markets. As Chair of the Pfizer Global COVID-19 Task Force, she developed and led an organization-wide task force overseeing the safety and well-being of 100,000 colleagues in more than 100 countries. Alongside this role, Ms. Silbermann served as Global President, Emerging Markets from 2018 to 2020, with operational and managerial responsibility for the entire Pfizer portfolio in China, Asia, Latin America, Africa and the Middle East, including the initial supply of COVID-19 vaccines in these regions. From 2012 to 2018, she served as President and General Manager, Pfizer Vaccines, creating the basis for much of Pfizer's current vaccine pipeline and portfolio and establishing and leading one of three inaugural global business units at Pfizer. Previously, Ms. Silbermann held the titles of Regional President, Latin America and Senior Vice President, Commercial Development at Pfizer.
Ms. Silbermann currently serves on the boards of LianBio and HilleVax, Inc. She also serves on the board of IAVI, an NGO focused on advancing vaccines and medicines for HIV-AIDS and other emerging infectious diseases, and is a board member for Meet the Writers, an education non-profit.
Ms. Silbermann holds a B.S. in Biology and French from Tufts University, an M.B.A. in Marketing and International Business from New York University and a Master of Administration degree in French Social and Political Sciences from New York University.
Source: Mallinckrodt
